{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:19:34Z","timestamp":1791231574091,"version":"4.1.0"},"reference-count":121,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antiphospholipid syndrome (APS) is an autoimmune prothrombotic disease characterized by thrombosis and\/or pregnancy complications caused by antiphospholipid antibodies (aPL). The history of APS can be traced back to observations made during screening programs for syphilis conducted in the mid-20th century, with identification of patients with the so-called biological false-positive serological reactions for syphilis. Initial observation linking aPL with recurrent miscarriages was first reported more than 40 years ago. Since then, our understanding of the pathogenesis and management of APS has evolved markedly. Although APS is an autoimmune disease, anticoagulation mainly with vitamin K antagonists (VKAs) rather than immunomodulation, is the treatment of choice for thrombotic APS. Direct acting oral anticoagulants are inferior to VKAs, especially those with triple-positive APS and arterial thrombosis. Inflammation, complement activation, and thrombosis in the placenta may contribute to pathogenesis of obstetric APS. Heparin, mainly low-molecular-weight heparin, and low-dose aspirin represent the treatments of choice for women with obstetric complications. Increasingly, immunomodulatory agents such as hydroxychloroquine for thrombotic and obstetric APS are being used, especially in patients who are refractory to present standard treatment.<\/jats:p>","DOI":"10.1055\/s-0042-1760333","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T23:54:51Z","timestamp":1673913291000},"page":"295-304","source":"Crossref","is-referenced-by-count":15,"title":["Evolution of Antiphospholipid Syndrome"],"prefix":"10.1055","volume":"49","author":[{"given":"Deepa R.J.","family":"Arachchillage","sequence":"additional","affiliation":[{"name":"Department of Immunology and Inflammation, Centre for Haematology, Imperial College London, London, United Kingdom"},{"name":"Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charis","family":"Pericleous","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,1,16]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"S Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"V Pengo","year":"2010","journal-title":"J Thromb Haemost"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1055\/s-0028-1142018","article-title":"Eine serodiagnostiche reaction bei syphilis","volume":"32","author":"A Wasserman","year":"1906","journal-title":"Dtsch Med Wochenschr"},{"key":"ref4","first-page":"1565","article-title":"Studies on the complement binding reaction in syphilis","volume":"20","author":"K Landsteiner","year":"1907","journal-title":"Wien Klin Wochenschr"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3181\/00379727-48-13365P","article-title":"A new serologically active phospholipid from beef heart","volume":"48","author":"M C Pangborn","year":"1941","journal-title":"Proc Soc Exp Biol Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0021-9258(18)72683-5","article-title":"Isolation and purification of a serologically active phospholipid from beef heart","volume":"143","author":"M C Pangborn","year":"1942","journal-title":"J Biol Chem"},{"issue":"06","key":"ref7","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.7326\/0003-4819-37-6-1156","article-title":"The incidence and etiologic background of chronic biologic false-positive reactions in serologic tests for syphilis","volume":"37","author":"J E Moore","year":"1952","journal-title":"Ann Intern Med"},{"issue":"03","key":"ref8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0021-9681(55)90039-4","article-title":"The natural history of systemic lupus erythematosus: an approach to its study through chronic biologic false positive reactors","volume":"1","author":"J E Moore","year":"1955","journal-title":"J Chronic Dis"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00005792-195412000-00001","article-title":"Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases","volume":"33","author":"A M Harvey","year":"1954","journal-title":"Medicine (Baltimore)"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.1962.03050440005002","article-title":"Auto-immune disease and the chronic biologic false-positive test for syphilis","volume":"182","author":"A M Harvey","year":"1962","journal-title":"JAMA"},{"issue":"24","key":"ref11","first-page":"1193","article-title":"The clinical significance of the biological false positive serologic reactor: a study of 113 cases","volume":"88","author":"A Knight","year":"1963","journal-title":"Can Med Assoc J"},{"issue":"06","key":"ref12","first-page":"1181","article-title":"Studies on the coagulation defect in a case of thrombocytopenic purpura complicated by thrombosis","volume":"22","author":"P M Aggeler","year":"1946","journal-title":"Am J Pathol"},{"issue":"08","key":"ref13","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood.V6.8.740.740","article-title":"Idiopathic hypoprothrombinemia associated with hemorrhagic diathesis, and the effect of vitamin K","volume":"6","author":"A B Ley","year":"1951","journal-title":"Blood"},{"issue":"07","key":"ref14","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/blood.V10.7.691.691","article-title":"Acquired circulating anticoagulants in systemic collagen disease; auto-immune thromboplastin deficiency","volume":"10","author":"P G Frick","year":"1955","journal-title":"Blood"},{"key":"ref15","first-page":"1","article-title":"A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus","volume":"21","author":"C L Conley","year":"1952","journal-title":"J Clin Invest"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1172\/JCI103237","article-title":"A disorder of blood coagulation in systemic lupus erythematosus","volume":"34","author":"S L Lee","year":"1955","journal-title":"J Clin Invest"},{"issue":"05","key":"ref17","first-page":"694","article-title":"Hypergammaglobulinemia, circulating anticoagulant, and biologic false positive Wassermann reaction; a study in two cases","volume":"49","author":"A B Laurell","year":"1957","journal-title":"J Lab Clin Med"},{"key":"ref18","first-page":"75","article-title":"Acquired inhibitors of blood coagulation","volume":"1","author":"D I Feinstein","year":"1972","journal-title":"Prog Hemost Thromb"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI109869","article-title":"Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant","volume":"66","author":"P Thiagarajan","year":"1980","journal-title":"J Clin Invest"},{"issue":"04","key":"ref20","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood.V68.4.869.869","article-title":"The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants","volume":"68","author":"P Thiagarajan","year":"1986","journal-title":"Blood"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1021\/bi00832a038","article-title":"Antibody binding and complement fixation by a liposomal model membrane","volume":"8","author":"C R Alving","year":"1969","journal-title":"Biochemistry"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0022-1759(80)90333-6","article-title":"A simple radioimmunoassay to determine binding of antibodies to lipid antigens","volume":"38","author":"M Smolarsky","year":"1980","journal-title":"J Immunol Methods"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(83)91267-9","article-title":"Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus","volume":"2","author":"E N Harris","year":"1983","journal-title":"Lancet"},{"issue":"03","key":"ref24","first-page":"738","article-title":"Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results","volume":"62","author":"S Loizou","year":"1985","journal-title":"Clin Exp Immunol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2141.1959.tb04036.x","article-title":"Circulating anticoagulants in disseminated lupus erythematosus","volume":"5","author":"L Sanchez Medal","year":"1959","journal-title":"Br J Haematol"},{"key":"ref26","first-page":"416","article-title":"Thrombosis in systemic lupus erythematosus despite circulating anticoagulants","volume":"62","author":"E J Bowie","year":"1963","journal-title":"J Lab Clin Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0140-6736(67)90852-5","article-title":"Myocardial infarction in a patient with a circulating anticoagulant","volume":"2","author":"D Green","year":"1967","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1136\/bmj.287.6398.1021","article-title":"Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant","volume":"287","author":"M L Boey","year":"1983","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1445-5994.1977.tb04410.x","article-title":"Recurrent venous thrombosis with a \u201clupus\u201d coagulation inhibitor in the absence of systemic lupus","volume":"7","author":"A Manoharan","year":"1977","journal-title":"Aust N Z J Med"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.0954-6820.1975.tb04897.x","article-title":"Intrauterine death and circulating anticoagulant (\u201cantithromboplastin\u201d)","volume":"197","author":"I M Nilsson","year":"1975","journal-title":"Acta Med Scand"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0140-6736(80)90361-X","article-title":"Possible relationship between lupus inhibitor and recurrent abortion in young women","volume":"2","author":"B G Firkin","year":"1980","journal-title":"Lancet"},{"issue":"05","key":"ref32","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1471-0528.1983.tb08950.x","article-title":"Chorea gravidarum associated with circulating lupus anticoagulant: successful outcome of pregnancy with prednisone and aspirin therapy. Case report","volume":"90","author":"W F Lubbe","year":"1983","journal-title":"Br J Obstet Gynaecol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/bmj.287.6399.1088","article-title":"Thrombosis, abortion, cerebral disease, and the lupus anticoagulant","volume":"287","author":"G R Hughes","year":"1983","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1056\/NEJM198507183130304","article-title":"Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus","volume":"313","author":"M D Lockshin","year":"1985","journal-title":"N Engl J Med"},{"issue":"21","key":"ref35","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1056\/NEJM198511213132104","article-title":"Obstetric complications associated with the lupus anticoagulant","volume":"313","author":"D W Branch","year":"1985","journal-title":"N Engl J Med"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/BF00270303","article-title":"Multiple venous and arterial thromboses associated with the lupus anticoagulant and antibodies to cardiolipin in the absence of SLE","volume":"5","author":"R A Asherson","year":"1985","journal-title":"Rheumatol Int"},{"issue":"05","key":"ref37","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/ard.48.5.362","article-title":"Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder","volume":"48","author":"C G Mackworth-Young","year":"1989","journal-title":"Ann Rheum Dis"},{"issue":"06","key":"ref38","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00005792-198911000-00004","article-title":"The \u201cprimary\u201d antiphospholipid syndrome: major clinical and serological features","volume":"68","author":"R A Asherson","year":"1989","journal-title":"Medicine (Baltimore)"},{"issue":"06","key":"ref39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00005792-198911000-00003","article-title":"Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients","volume":"68","author":"D Alarc\u00f3n-Segovia","year":"1989","journal-title":"Medicine (Baltimore)"},{"issue":"03","key":"ref40","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/ard.46.3.251","article-title":"Disseminated intravascular coagulation, antiphospholipid antibodies, and ischaemic necrosis of extremities","volume":"46","author":"A G Bird","year":"1987","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"ref41","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/art.1780301013","article-title":"An unusual syndrome of a devastating noninflammatory vasculopathy associated with anticardiolipin antibodies: report of two cases","volume":"30","author":"S B Ingram","year":"1987","journal-title":"Arthritis Rheum"},{"issue":"04","key":"ref42","first-page":"370","article-title":"A maternal death due to thrombotic disease associated with anticardiolipin antibody","volume":"111","author":"R W Bendon","year":"1987","journal-title":"Arch Pathol Lab Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1136\/bmj.296.6635.1505","article-title":"Fatal cardiac failure due to myocardial microthrombi in systemic lupus erythematosus","volume":"296","author":"J H Brown","year":"1988","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"04","key":"ref44","first-page":"508","article-title":"The catastrophic antiphospholipid syndrome","volume":"19","author":"R A Asherson","year":"1992","journal-title":"J Rheumatol"},{"issue":"11","key":"ref45","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1073\/pnas.87.11.4120","article-title":"Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H)","volume":"87","author":"H P McNeil","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/0140-6736(90)91374-J","article-title":"Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor","volume":"335","author":"M Galli","year":"1990","journal-title":"Lancet"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0140-6736(90)91697-9","article-title":"Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease","volume":"336","author":"E Matsuura","year":"1990","journal-title":"Lancet"},{"issue":"12","key":"ref48","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/intimm\/3.12.1217","article-title":"Molecular definition of human beta 2-glycoprotein I (beta 2-GPI) by cDNA cloning and inter-species differences of beta 2-GPI in alternation of anticardiolipin binding","volume":"3","author":"E Matsuura","year":"1991","journal-title":"Int Immunol"},{"issue":"06","key":"ref49","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrrheum.2011.52","article-title":"Pathogenesis of antiphospholipid syndrome: understanding the antibodies","volume":"7","author":"P L Meroni","year":"2011","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"ref50","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMra1112830","article-title":"The pathogenesis of the antiphospholipid syndrome","volume":"368","author":"B Giannakopoulos","year":"2013","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"100610","DOI":"10.1016\/j.blre.2019.100610","article-title":"The role of beta-2-glycoprotein I in health and disease associating structure with function: more than just APS","volume":"39","author":"T McDonnell","year":"2020","journal-title":"Blood Rev"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1042\/bj2770387","article-title":"Complete nucleotide and deduced amino acid sequence of human beta 2-glycoprotein I","volume":"277","author":"A Steinkasserer","year":"1991","journal-title":"Biochem J"},{"issue":"22","key":"ref53","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.1093\/emboj\/18.22.6228","article-title":"Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome","volume":"18","author":"R Schwarzenbacher","year":"1999","journal-title":"EMBO J"},{"issue":"05","key":"ref54","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1182\/blood-2005-05-1943","article-title":"Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change","volume":"107","author":"B de Laat","year":"2006","journal-title":"Blood"},{"issue":"12","key":"ref55","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1177\/0961203314540354","article-title":"Domain I: the hidden face of antiphospholipid syndrome","volume":"23","author":"C Pericleous","year":"2014","journal-title":"Lupus"},{"issue":"05","key":"ref56","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1055\/s-0037-1601329","article-title":"The significance of antibodies against domain I of beta-2 glycoprotein I in antiphospholipid syndrome","volume":"44","author":"H Kelchtermans","year":"2018","journal-title":"Semin Thromb Hemost"},{"issue":"04","key":"ref57","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3324\/haematol.2018.198119","article-title":"New insight into antiphospholipid syndrome: antibodies to \u03b22glycoprotein I-domain 5 fail to induce thrombi in rats","volume":"104","author":"P Durigutto","year":"2019","journal-title":"Haematologica"},{"issue":"08","key":"ref58","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/art.39187","article-title":"Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against \u03b22-glycoprotein I domain 1 and domain 4\/5: ratio of anti-domain 1 to anti-domain 4\/5 as a useful new biomarker for antiphospholipid syndrome","volume":"67","author":"L Andreoli","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"01","key":"ref59","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-016-1018-x","article-title":"Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers","volume":"18","author":"D Roggenbuck","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"22","key":"ref60","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1182\/blood-2013-11-537704","article-title":"A non-complement-fixing antibody to \u03b22 glycoprotein I as a novel therapy for antiphospholipid syndrome","volume":"123","author":"C Agostinis","year":"2014","journal-title":"Blood"},{"issue":"04","key":"ref61","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/rheumatology\/keu360","article-title":"Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of \u03b22-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis","volume":"54","author":"C Pericleous","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"06","key":"ref62","doi-asserted-by":"crossref","first-page":"e0156407","DOI":"10.1371\/journal.pone.0156407","article-title":"Measuring IgA anti-\u03b22-glycoprotein I and IgG\/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome","volume":"11","author":"C Pericleous","year":"2016","journal-title":"PLoS One"},{"issue":"04","key":"ref63","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood-2004-09-3387","article-title":"IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis","volume":"105","author":"B de Laat","year":"2005","journal-title":"Blood"},{"issue":"09","key":"ref64","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1111\/jth.13389","article-title":"Role of anti-domain 1-\u03b22 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome","volume":"14","author":"A S De Craemer","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref65","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1055\/s-0037-1603936","article-title":"Prevalence and thrombotic risk assessment of anti-\u03b22 glycoprotein I domain I antibodies: a systematic review","volume":"44","author":"M Radin","year":"2018","journal-title":"Semin Thromb Hemost"},{"issue":"01","key":"ref66","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/rheumatology\/kez239","article-title":"Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?","volume":"59","author":"C Pericleous","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"keac596","DOI":"10.1093\/rheumatology\/keac596","article-title":"Antiphospholipid antibody positivity in early systemic lupus erythematosus is associated with subsequent vascular events","author":"N Farina","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaut.2018.02.002","article-title":"Beyond thrombosis: anti-\u03b22GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome","volume":"90","author":"C B Chighizola","year":"2018","journal-title":"J Autoimmun"},{"issue":"12","key":"ref69","doi-asserted-by":"crossref","first-page":"7097","DOI":"10.4049\/jimmunol.169.12.7097","article-title":"Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies","volume":"169","author":"G M Iverson","year":"2002","journal-title":"J Immunol"},{"issue":"01","key":"ref70","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/art.22306","article-title":"Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43","volume":"56","author":"Y Ioannou","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"12","key":"ref71","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1002\/art.30633","article-title":"Immune responses against domain I of \u03b2(2)-glycoprotein I are driven by conformational changes: domain I of \u03b2(2)-glycoprotein I harbors a cryptic immunogenic epitope","volume":"63","author":"B de Laat","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"26","key":"ref72","doi-asserted-by":"crossref","first-page":"15542","DOI":"10.1073\/pnas.95.26.15542","article-title":"Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI","volume":"95","author":"G M Iverson","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"04","key":"ref73","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1055\/s-0040-1705115","article-title":"Antiphosphatidylserine\/prothrombin antibodies: an update on their association with clinical manifestations of antiphospholipid syndrome","volume":"120","author":"M Radin","year":"2020","journal-title":"Thromb Haemost"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12026-013-8421-z","article-title":"Anti-phosphatidylserine\/prothrombin antibodies: an additional diagnostic marker for APS?","volume":"56","author":"F Pregnolato","year":"2013","journal-title":"Immunol Res"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"975704","DOI":"10.1155\/2015\/975704","article-title":"Anti-phosphatidylserine\/prothrombin antibodies are associated with adverse pregnancy outcomes","volume":"2015","author":"P \u017digon","year":"2015","journal-title":"J Immunol Res"},{"issue":"04","key":"ref76","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/jth.13257","article-title":"Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study","volume":"14","author":"T Marchetti","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref77","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1515\/cclm-2017-0502","article-title":"Antiphosphatidylserine\/prothrombin antibodies (aPS\/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome","volume":"56","author":"H Shi","year":"2018","journal-title":"Clin Chem Lab Med"},{"issue":"09","key":"ref78","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1111\/jth.15792","article-title":"Anti-phosphatidylserine prothrombin antibodies as a predictor of the lupus anticoagulant in an all-comer population","volume":"20","author":"M Pham","year":"2022","journal-title":"J Thromb Haemost"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1757633","article-title":"Frequency and clinical significance anti-PS\/PT antibodies in patients with antiphospholipid syndrome - single centre observational study in the United Kingdom","author":"H Noble","year":"2022","journal-title":"Semin Thromb Hemost"},{"issue":"06","key":"ref80","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1055\/s-0038-1646476","article-title":"Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin","volume":"66","author":"E M Bevers","year":"1991","journal-title":"Thromb Haemost"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3389\/fimmu.2019.00376","article-title":"Reliability of lupus anticoagulant and anti-phosphatidylserine\/prothrombin autoantibodies in antiphospholipid syndrome: a multicenter study","volume":"10","author":"S Sciascia","year":"2019","journal-title":"Front Immunol"},{"issue":"01","key":"ref82","first-page":"83","article-title":"Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants","volume":"86","author":"J Arnout","year":"2001","journal-title":"Thromb Haemost"},{"issue":"11","key":"ref83","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1136\/annrheumdis-2014-205663","article-title":"The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review","volume":"74","author":"S Sciascia","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"ref84","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/acr.22066","article-title":"Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature","volume":"65","author":"L Andreoli","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"06","key":"ref85","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"R Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"02","key":"ref86","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2249.1993.tb07978.x","article-title":"Induction of phospholipid-binding antibodies in mice and rabbits by immunization with human beta 2 glycoprotein 1 or anticardiolipin antibodies alone","volume":"93","author":"S S Pierangeli","year":"1993","journal-title":"Clin Exp Immunol"},{"issue":"01","key":"ref87","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jri.2007.02.007","article-title":"Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation","volume":"77","author":"J E Salmon","year":"2008","journal-title":"J Reprod Immunol"},{"issue":"03","key":"ref88","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0028-2243(91)90021-C","article-title":"Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies","volume":"41","author":"H J Out","year":"1991","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"01","key":"ref89","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/0891693031000067322","article-title":"The role of complement in pregnancy and fetal loss","volume":"36","author":"G Girardi","year":"2003","journal-title":"Autoimmunity"},{"issue":"07","key":"ref90","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1191\/0961203303lu397oa","article-title":"Activation of complement mediates antiphospholipid antibody-induced pregnancy loss","volume":"12","author":"J E Salmon","year":"2003","journal-title":"Lupus"},{"issue":"11","key":"ref91","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nm1121","article-title":"Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation","volume":"10","author":"G Girardi","year":"2004","journal-title":"Nat Med"},{"issue":"03","key":"ref92","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.rdc.2006.05.002","article-title":"Catastrophic antiphospholipid syndrome","volume":"32","author":"R Cervera","year":"2006","journal-title":"Rheum Dis Clin North Am"},{"issue":"06","key":"ref93","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/1759720X13502919","article-title":"Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease","volume":"5","author":"C L Aguiar","year":"2013","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"07","key":"ref94","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/014107688708000716","article-title":"Antiphospholipid antibody syndrome: a review","volume":"80","author":"P J Bingley","year":"1987","journal-title":"J R Soc Med"},{"issue":"04","key":"ref95","doi-asserted-by":"crossref","first-page":"303","DOI":"10.7326\/0003-4819-117-4-303","article-title":"Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients","volume":"117","author":"M H Rosove","year":"1992","journal-title":"Ann Intern Med"},{"issue":"15","key":"ref96","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJM199504133321504","article-title":"The management of thrombosis in the antiphospholipid-antibody syndrome","volume":"332","author":"M A Khamashta","year":"1995","journal-title":"N Engl J Med"},{"issue":"12","key":"ref97","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"M A Crowther","year":"2003","journal-title":"N Engl J Med"},{"issue":"05","key":"ref98","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","article-title":"A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","volume":"3","author":"G Finazzi","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref99","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/jama.291.5.576","article-title":"Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke","volume":"291","author":"S R Levine","year":"2004","journal-title":"JAMA"},{"issue":"09","key":"ref100","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"H Cohen","year":"2016","journal-title":"Lancet Haematol"},{"issue":"13","key":"ref101","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"V Pengo","year":"2018","journal-title":"Blood"},{"issue":"06","key":"ref102","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"S C Woller","year":"2022","journal-title":"Blood Adv"},{"issue":"01","key":"ref103","doi-asserted-by":"crossref","first-page":"102711","DOI":"10.1016\/j.autrev.2020.102711","article-title":"Direct oral anticoagulants in antiphospholipid syndrome: meta-analysis of randomized controlled trials","volume":"20","author":"V Dufrost","year":"2021","journal-title":"Autoimmun Rev"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejim.2020.05.012","article-title":"Direct oral anticoagulants versus vitamin K antagonists in antiphospholipid syndrome: a meta-analysis","volume":"79","author":"P Cerd\u00e0","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"10","key":"ref105","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"J Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"issue":"02","key":"ref106","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.16308","article-title":"Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47-58): use of direct acting oral anticoagulants","volume":"189","author":"D RJ Arachchillage","year":"2020","journal-title":"Br J Haematol"},{"key":"ref107","first-page":"S0735","article-title":"Direct oral anticoagulants vs vitamin-K antagonists in thrombotic antiphospholipid syndrome: meta-analysis of randomized controlled trials","author":"C D Khairani","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"02","key":"ref108","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/bjh.14632","article-title":"Pathogenesis and management of antiphospholipid syndrome","volume":"178","author":"D RJ Arachchillage","year":"2017","journal-title":"Br J Haematol"},{"issue":"10","key":"ref109","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/jth.12363","article-title":"Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients","volume":"11","author":"A Schmidt-Tanguy","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref111","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1093\/oxfordjournals.humrep.a135907","article-title":"High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies","volume":"10","author":"R S Rai","year":"1995","journal-title":"Hum Reprod"},{"issue":"03","key":"ref112","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJM199707173370302","article-title":"Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss","volume":"337","author":"C A Laskin","year":"1997","journal-title":"N Engl J Med"},{"issue":"03","key":"ref113","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/art.10957","article-title":"Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies","volume":"48","author":"G Triolo","year":"2003","journal-title":"Arthritis Rheum"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.314.7076.253","article-title":"Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)","volume":"314","author":"R Rai","year":"1997","journal-title":"BMJ"},{"issue":"03","key":"ref115","first-page":"408","article-title":"Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment","volume":"100","author":"R G Farquharson","year":"2002","journal-title":"Obstet Gynecol"},{"issue":"05","key":"ref116","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/bjh.12848","article-title":"The chequered history of the antiphospholipid syndrome","volume":"165","author":"D Jayakody Arachchillage","year":"2014","journal-title":"Br J Haematol"},{"issue":"04","key":"ref117","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/17474086.2017.1300522","article-title":"Diagnosis and management of catastrophic antiphospholipid syndrome","volume":"10","author":"O Carmi","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"07","key":"ref118","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/rheumatology\/key082","article-title":"The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients","volume":"57","author":"I Rodr\u00edguez-Pint\u00f3","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"06","key":"ref119","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/ard.2010.142042","article-title":"Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study","volume":"70","author":"A Ruffatti","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"ref120","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2011-03-340232","article-title":"Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study","volume":"118","author":"V Pengo","year":"2011","journal-title":"Blood"},{"issue":"07","key":"ref121","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1002\/art.22663","article-title":"Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals","volume":"56","author":"D Erkan","year":"2007","journal-title":"Arthritis Rheum"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/qa2yb4","article-title":"Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and\/or non-criteria manifestations of antiphospholipid syndrome: study protocol","author":"S Sciascia","year":"2022","journal-title":"Clin Exp Rheumatol"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1760333.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T21:02:32Z","timestamp":1701723752000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1760333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":121,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2023,3,7]]},"published-print":{"date-parts":[[2023,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1760333","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,16]]}}}